These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11511041)

  • 21. Complement activation and inflammation triggered by model biomaterial surfaces.
    Tang L; Liu L; Elwing HB
    J Biomed Mater Res; 1998 Aug; 41(2):333-40. PubMed ID: 9638539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement activation on poly(ethylene oxide)-like radiofrequency glow discharge-deposited surfaces.
    Szott LM; Stein MJ; Ratner BD; Horbett TA
    J Biomed Mater Res A; 2011 Jan; 96(1):150-61. PubMed ID: 21105163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers.
    Janatova J
    ASAIO J; 2000; 46(6):S53-62. PubMed ID: 11110295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of surface bound complement at increasing serum anticoagulant concentrations.
    Arvidsson S; Askendal A; Lindahl TL; Tengvall P
    Colloids Surf B Biointerfaces; 2008 Apr; 62(2):214-9. PubMed ID: 18006286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoporesize affects complement activation.
    Ferraz N; Nilsson B; Hong J; Karlsson Ott M
    J Biomed Mater Res A; 2008 Dec; 87(3):575-81. PubMed ID: 18186072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b.
    Ekdahl KN; Nilsson B
    J Immunol; 1995 Jun; 154(12):6502-10. PubMed ID: 7539023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deposition of complement C3 and factor H in tissue traumatized by burn injury.
    Sriramarao P; DiScipio RG
    Immunopharmacology; 1999 May; 42(1-3):195-202. PubMed ID: 10408380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C3, C5, and factor B bind to chitosan without complement activation.
    Marchand C; Bachand J; Périnêt J; Baraghis E; Lamarre M; Rivard GE; De Crescenzo G; Hoemann CD
    J Biomed Mater Res A; 2010 Jun; 93(4):1429-41. PubMed ID: 19927329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The complement factor H-related proteins.
    Medjeral-Thomas N; Pickering MC
    Immunol Rev; 2016 Nov; 274(1):191-201. PubMed ID: 27782332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro.
    Andersson J; Sanchez J; Ekdahl KN; Elgue G; Nilsson B; Larsson R
    J Biomed Mater Res A; 2003 Nov; 67(2):458-66. PubMed ID: 14566786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
    Strunk RC; Webster RO
    Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
    Vachino G; Gelfand JA; Atkins MB; Tamerius JD; Demchak P; Mier JW
    Blood; 1991 Nov; 78(10):2505-13. PubMed ID: 1824247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood protein interactions with chromium surfaces.
    Wälivaara B; Askendal A; Krozer A; Lundström I; Tengvall P
    J Biomater Sci Polym Ed; 1996; 8(1):49-62. PubMed ID: 8933290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activation in extracorporeal circuits.
    Chenoweth DE
    Ann N Y Acad Sci; 1987; 516():306-13. PubMed ID: 3439733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation on solid surfaces as determined by C3 deposition and hemolytic consumption.
    Liu L; Elwing H
    J Biomed Mater Res; 1994 Jul; 28(7):767-73. PubMed ID: 8083244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits.
    Fung M; Loubser PG; Undar A; Mueller M; Sun C; Sun WN; Vaughn WK; Fraser CD
    J Thorac Cardiovasc Surg; 2001 Jul; 122(1):113-22. PubMed ID: 11436043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Ringdal MA; Videm V
    Ann Thorac Surg; 1995 Dec; 60(6):1755-61. PubMed ID: 8787476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic regulation of complement activation in extracorporeal circuits and intravascular treatments with special reference to the alternative pathway amplification loop.
    Ekdahl KN; Fromell K; Mannes M; Grinnemo KH; Huber-Lang M; Teramura Y; Nilsson B
    Immunol Rev; 2023 Jan; 313(1):91-103. PubMed ID: 36258635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfated alginate microspheres associate with factor H and dampen the inflammatory cytokine response.
    Arlov Ø; Skjåk-Bræk G; Rokstad AM
    Acta Biomater; 2016 Sep; 42():180-188. PubMed ID: 27296843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.